Quick Answer
Yubo International Biotech Ltd reported Operating Income Loss of -$1.19 million for the year ending 2025.
- Yubo International Biotech Ltd showed an increase of +32.9% in Operating Income Loss from 2024 to 2025.
- This data is from Yubo International Biotech Ltd's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2011 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2011 to 2025), Yubo International Biotech Ltd's Operating Income Loss has declined by 1,384.6%.
- Historical annual values: Fiscal year 2025: -$1.19 million | Fiscal year 2024: -$1.77 million | Fiscal year 2023: -$1.19 million | Fiscal year 2022: -$1.21 million | Fiscal year 2021: -$1.54 million | Fiscal year 2020: -$711.8 thousand | Fiscal year 2020: -$29.0 thousand | Fiscal year 2019: -$48.0 thousand | Fiscal year 2018: -$58.0 thousand | Fiscal year 2017: -$149.0 thousand | Fiscal year 2016: -$63.0 thousand | Fiscal year 2015: -$58.0 thousand | Fiscal year 2014: -$55.0 thousand | Fiscal year 2013: -$60.0 thousand | Fiscal year 2012: -$47.0 thousand | Fiscal year 2011: -$80.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: